【JP:4892】Stock Price

Cyfuse is a regenerative medicine venture company founded in 2010. Using innovative three-dimensional cell layering technology, the company provides three-dimensional tissues and organs made entirely from cells as "3D cell products." This technology aims to advance medical treatment through applications in regenerative medicine and drug discovery.

Cyfuse's business is divided into three main areas: regenerative medicine, drug discovery support, and devices. In the regenerative medicine field, the company conducts research, development, and commercial manufacturing of cell products. It focuses primarily on autologous cell transplantation using patients' own cells, with product development underway in peripheral nerve regeneration, bone and cartilage regeneration, and blood vessel regeneration.

In the drug discovery support field, the company develops 3D cell products composed entirely of human cells, such as "human 3D mini livers," to support drug development activities at pharmaceutical companies and non-clinical testing service providers. The company is also exploring the potential of these products as alternatives to animal testing.

In the device field, the company develops and sells automated equipment and related devices, including bio-3D printers. This supports the mechanization and automation of manufacturing processes for regenerative medicine products, with the goal of establishing commercial production systems.

Cyfuse leverages its proprietary core technology and strengthens partnerships with companies and medical institutions to commercialize regenerative medicine products. Through these efforts, the company aims to accelerate product development and provide new treatment options in the regenerative medicine field.

Cytofuse is pursuing growth in the regenerative medicine field based on innovative three-dimensional cell stacking technology. The company operates across three business areas—regenerative medicine, drug discovery support, and device development—by leveraging its technology to create three-dimensional tissues and organs using cells alone. Through these efforts, the company aims to contribute to medical advancement and strengthen its presence in global markets.

Under its medium-term management plan, the company will secure baseline revenue through the expansion of bio-3D printers while advancing the commercialization of cell products for research tissues. Ultimately, the company aims to obtain regulatory approval for regenerative medicine products and maximize business value. This will establish the company's position as a regenerative medicine venture and enable sustained growth.

In the regenerative medicine field, the company is advancing clinical development of multiple pipelines in cooperation with development partners. This aims to achieve regulatory approval for regenerative medicine products and establish them as long-term business pillars. In the drug discovery support field, the company is commercializing toxicity evaluation models using liver tissue structures to establish itself as a medium-term growth driver.

In the device field, the company is expanding the adoption of bio-3D printers and pursuing global standardization of its core technology. Anticipating growth in the regenerative medicine ecosystem, the company is expanding the market for equipment and consumables to drive the industrialization of regenerative medicine. This will create new market opportunities in the regenerative medicine field and enable business expansion.